Shocking new link discovered between Ozempic and CANCER
Game-changing weight loss jabs could help ward off up to 14 types of cancer, world-leading experts suggest.
Mounjaro, Ozempic and other fat-melting injections have ushered in a new era in the war on obesity, but have also been linked to other health benefits, such as slashing the risk of heart attacks, strokes and kidney disease.
Now scientists have discovered the drugs could reduce the risk of a range weight-related cancers including hard to diagnose types such as of pancreatic, kidney and ovarian.
The breakthrough research found the jabs were most effective at slashing the risk of colon and rectal cancers specifically.
Both have seen a disturbing rises in cases in the under 50s in recent years baffling doctors around the globe.
American scientists, who carried out the trial, said the findings show the drugs have a 'preventative effect' in people at higher risk of these 14 diseases.
However, they cautioned further research was necessary to confirm their findings.
Researchers also didn't speculate why the drugs, which belong to class of medications called GLP-1 agonists, might lower a patient's chances of cancer.
Lucas Mavromatis, an expert in obesity at NYU Grossman School of Medicine in New York and study lead author, said: 'Although obesity is now recognized as an increasingly important cause of cancer in the United States and worldwide, no medications have been proven to lower the cancer risk associated with obesity.
'Our study begins to fill that gap by evaluating GLP-1 receptor agonists, a relatively new but widely prescribed medication that treats diabetes, obesity, and related conditions.
'Our results suggest they may modestly cut the chance of developing certain cancers—especially cancers of the colon and rectum—and reduce rates of death due to all causes.
'These data are reassuring, but more studies are required to prove causation.'
In the study, researchers studied data from more than 170,000 obese patients with diabetes, aged 57 on average.
Over a follow-up of a decade, they compared the cancer risk among patients on GLP-1 agonists against those on DDP-4 inhibitors, another diabetes medication.
The 14 cancers assessed included oesophageal, colon, rectum, stomach, liver, gallbladder, pancreas, kidney and post-menopausal breast.
Ovarian, endometrium and thyroid, as well as multiple myeloma and meningiomas, were the others.
They found those on GLP-1s had a 7 per cent lower risk of developing an obesity-related cancer than patients on DDP-4 inhibitors.
When other health benefits were factored in, these patients were also 8 per cent less likely to die over the 10-year period.
Overall the biggest reduction was seen for colon (16 per cent) and rectal (28 per cent) cancers.
These benefits were greater among women compared to men, with obese females on GLP-1s recording an 8 per cent lower risk of obesity-related cancer and 20 per cent lower risk of all causes of death compared to women treated with DDP-4 inhibitors.
The findings will be presented in full next week at the American Society for Clinical Oncology (ASCO) conference in Chicago.
Dr Robin Zon, ASCO president, said: 'This trial raises an intriguing hypothesis: that the increasingly popular GLP-1 medications used to treat diabetes and obesity might offer some benefit in reducing the risk of developing cancer.
'I see many patients with obesity, and given the clear link between cancer and obesity, defining the clinical role of GLP-1 medications in cancer prevention is important.
'Though this trial does not establish causation, it hints that these drugs might have a preventative effect.
'Future research is needed to validate these findings, including in patients who do not have diabetes.'
The jabs were originally developed as a diabetes treatment, but in recent years has become one of the world's most in-demand weight-loss drugs, with a host of celebrities—including Elon Musk and Boris Johnson—revealing they take it in a bid to slim down.
At least half a million NHS patients and some 15million in the US are now thought to be using weight loss jabs, which can help patients lose up to 20 per cent of their bodyweight in just a few months.
Obesity itself increases the chances of person suffering serious health conditions that can damage the heart, such as high blood pressure, as well as cancers.
Around two in three adults in the UK are obese or overweight, giving the country one of the highest obesity rates in Europe. In the US, the figure stands at almost 75 per cent.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
29 minutes ago
- Daily Mail
Eating specific type of bread linked to deadly colon cancer, shock study finds
Regularly eating white, packaged bread could raise the risk of dying from colon cancer by more than a third, a new trial has suggested. Frequently consuming ham, bacon and sugary drinks carry the same increased chance of cancer death, US researchers found. Meanwhile, eating plenty of 'dark yellow' vegetables such as sweet potatoes and carrots, and drinking coffee, could offer some protection. Over the last 30 years, young diagnoses of the disease have shot up by 80 per cent across the globe, research shows. Scientists have suggested a host of factors are likely behind the phenomenon—from increased pollution to rising obesity and even invisible particles of plastic in drinking water. Now, US specialists have uncovered evidence that eating a high 'inflammatory diet' is could be an 'overlooked' cause. Foods that fall under the category include processed meats like bacon, ham and sausages, sugary drinks, refined carbohydrates like white pasta or bread and offal. Yet dark yellow vegetables like sweet potatoes and carrots, as well as coffee, wine and, surprisingly, pizza are all classed as 'anti-inflammatory foods' under the empirical dietary inflammatory pattern (EDIP)—a global tool that assesses foods on their 'inflammatory potential'. Pizza was classed as anti-inflammatory as it contains cooked tomatoes, which are high in the powerful antioxidant, lycopene. The study found colon cancer patients who ate more inflammatory food than 80 per cent of the volunteers had a 36 per cent higher risk of dying from their cancer than those who ate very little. Experts, presenting the findings at the American Society of Clinical Oncology (ASCO) conference in Chicago, said that, while there is not yet enough evidence to support the anti-inflammatory diet as a recommendation for cancer patients, this may be the case in the near future. In the study, scientists tracked 1,625 patients with colon cancer that had spread to the nearby lymph glands, but not beyond. All volunteers completed food questionnaires about how often they consumed foods that fell under 18 food groups—nine pro-inflammatory and nine anti-inflammatory. Over a follow-up of three years researchers found that patients in the top 20 per cent of most inflammatory diets had a 36 per cent higher risk of dying from their cancer than those who consumed least. Those in the top 20 per cent also had an 87 per cent higher risk of death overall than the bottom 20 per cent. When exercise was taken into account, those who consumed the least inflammatory diet and maintained the highest levels of physical activity had a 63 per cent lower risk of death. ASCO president and top cancer specialist Julie Gralow said the findings suggested 'we need to be essentially prescribing healthy diet and exercise. The combination of the two are synergistic.' Dr Catherine Elliott, Cancer Research UK's director of research, also told MailOnline: 'This study adds to interesting emerging evidence about the role of inflammation in the progression of colon cancer. 'We need more high-quality research like this to help us uncover more about how our diet influences cancer outcomes. 'When it comes to food and cancer risk, our overall diet is far more important than any single food or ingredient. 'A healthy, balanced diet includes eating lots of fruit, vegetables, wholegrains, and healthy sources of protein like beans and chicken. 'Cutting down on processed and red meats, and foods high in fat, sugar and salt also helps.' It comes as other research presented at ASCO found colon cancer patients who stuck to an anti-inflammatory diet reduced their risk of the disease spreading or recurring by 38 per cent. The study, by scientists at Maimonides Medical Centre in New York, tracked the food habits of 796 patients who had been diagnosed with the disease between 2015 and 2023. They also found consuming a diet high in ultra-processed foods raised the odds almost two and a half times. 'Ultra-processed foods increase inflammation and colon cancer risk while anti-inflammatory diets offer protective benefits,' they said. 'Dietary intervention must play a role in preventing cancer.' Colon cancer, long considered a disease of old age, is increasingly striking people in their 20s, 30s and 40s in a phenomenon that has baffled doctors around the world. Over the last 30 years, young diagnoses of the disease have shot up by 80 per cent across the globe. Around 32,000 cases of colon cancer are diagnosed every year in the UK and 142,000 in the US.
Reuters
an hour ago
- Reuters
Indivior to delist from London Stock Exchange, maintain Nasdaq listing
June 2 (Reuters) - Pharma firm Indivior (INDV.L), opens new tab said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align with its U.S.-centric business. The company, known for its opioid addiction treatment, joins a growing number of companies delisting from London, as lower valuations and weak investor appetite continue to drive firms toward U.S. markets. Shares of Indivior, which floated in London in late 2014, have dropped more than 60% from record highs hit in June 2018. The company said over 80% of its revenue now comes from the U.S., with the Nasdaq (NDAQ.O), opens new tab accounting for about 75% of recent trading volumes. The delisting aims to streamline operations and reflect the company's strategic focus on the U.S. market, it said. Indivior moved its primary listing to the United States last year. The decision to delist from London comes just months after Indivior overhauled its management. Earlier this year, it appointed David Wheadon as chair and Joe Ciaffoni as CEO.
Geeky Gadgets
an hour ago
- Geeky Gadgets
Unlock this Secret Workflow Hack that Combines Claude 4 & Gemini 2.5
What if the secret to unlocking your most productive workflow wasn't about choosing the best tool, but about how you combine them? In a world where artificial intelligence is reshaping how we work, the pairing of Claude 4 and Gemini 2.5 offers a innovative approach that many professionals are overlooking. Imagine seamlessly transitioning from raw data analysis to polished storytelling, or from technical precision to strategic insight—all within one integrated system. These two AI powerhouses, each with their own unique strengths, aren't just tools; they're collaborative partners that can transform the way you tackle complex projects. Yet, most people miss the opportunity to harness their full potential together. In this perspective, Grace Leung explores how Claude 4 and Gemini 2.5 complement each other to create a workflow that's both efficient and impactful. You'll discover how Gemini's technical prowess in processing multimodal data and Claude's strategic depth in refining insights can work in tandem to elevate your results. Whether you're managing large datasets, crafting compelling narratives, or making high-stakes decisions, this workflow offers a fresh way to approach your challenges. By the end, you might just rethink how you integrate AI into your daily processes—and uncover untapped possibilities hiding in plain sight. Claude 4 & Gemini 2.5 Synergy What Makes Each AI Model Unique? Claude 4 and Gemini 2.5 are designed to address different challenges, making them ideal partners for a wide range of workflows. Their distinct strengths complement each other, allowing users to tackle complex tasks with greater ease and precision. Gemini 2.5: Renowned for its speed, scalability, and ability to handle large datasets, Gemini 2.5 is a robust tool for technical and data-intensive tasks. Its extensive context window allows it to process multimodal inputs, including text, images, and structured data. This makes it particularly valuable for analyzing complex datasets, building prototypes, or managing large-scale projects. Gemini's technical efficiency ensures reliable and consistent results, even under demanding conditions. Renowned for its speed, scalability, and ability to handle large datasets, Gemini 2.5 is a robust tool for technical and data-intensive tasks. Its extensive context window allows it to process multimodal inputs, including text, images, and structured data. This makes it particularly valuable for analyzing complex datasets, building prototypes, or managing large-scale projects. Gemini's technical efficiency ensures reliable and consistent results, even under demanding conditions. Claude 4: Focused on strategy, storytelling, and detailed analysis, Claude 4 excels in refining insights and crafting polished outputs. Its autonomous memory system enables it to maintain contextual understanding across multiple stages of a project, making sure seamless updates and continuity. Claude is particularly effective for high-level decision-making, creating visually engaging presentations, and developing narratives that resonate with audiences. How to Combine Their Strengths To fully harness the potential of Claude 4 and Gemini 2.5, a sequential workflow that uses their individual strengths is recommended. This approach ensures that each model contributes its unique capabilities to the overall process. 1. Begin with Gemini 2.5: Start by using Gemini to process and analyze large datasets or multimodal inputs. Its technical precision and scalability provide a solid foundation for your project, allowing you to extract raw insights and identify key patterns efficiently. 2. Transition to Claude 4: Once the data has been processed, shift to Claude for deeper analysis, storytelling, and strategic refinement. Claude's ability to contextualize information and present it in a compelling manner ensures that your outputs are both insightful and impactful. This workflow allows you to combine Gemini's technical expertise with Claude's strategic depth, resulting in outputs that are both data-driven and contextually rich. By dividing tasks according to each model's strengths, you can save time while making sure high-quality results. The Workflow Most People Miss : Claude 4 + Gemini 2.5 Watch this video on YouTube. Explore further guides and articles from our vast library that you may find relevant to your interests in Claude 4. Practical Applications The integration of Claude 4 and Gemini 2.5 offers fantastic potential across various industries. Their combined capabilities can be applied to a wide range of scenarios, enhancing workflows and delivering superior outcomes. Strategic Dashboards: Use Gemini to analyze large datasets and extract raw insights. Claude can then organize these insights into actionable intelligence, complete with visual aids and strategic recommendations tailored to decision-makers. Use Gemini to analyze large datasets and extract raw insights. Claude can then organize these insights into actionable intelligence, complete with visual aids and strategic recommendations tailored to decision-makers. Audience Intelligence: Process customer data with Gemini to uncover trends, behaviors, and preferences. Claude can interpret this data to craft targeted messaging and develop marketing campaigns that resonate with specific audiences. Process customer data with Gemini to uncover trends, behaviors, and preferences. Claude can interpret this data to craft targeted messaging and develop marketing campaigns that resonate with specific audiences. AI-Powered Speaking Coaching: Analyze speaking patterns and presentation data using Gemini. Claude can refine scripts, suggest improvements, and even generate audio for practice sessions, helping users enhance their communication skills. Analyze speaking patterns and presentation data using Gemini. Claude can refine scripts, suggest improvements, and even generate audio for practice sessions, helping users enhance their communication skills. Visual Storytelling for Presentations: Gemini provides the data analysis needed for creating charts, graphs, and visuals. Claude transforms these into compelling narratives, making sure that presentations are both informative and engaging. Gemini provides the data analysis needed for creating charts, graphs, and visuals. Claude transforms these into compelling narratives, making sure that presentations are both informative and engaging. Collaborative Critique Workflow: Let Gemini generate initial outputs, such as drafts or prototypes, and have Claude critique and enhance them. This iterative process ensures polished, high-quality deliverables that meet professional standards. Why This Workflow Works The effectiveness of this workflow lies in the complementary nature of Claude 4 and Gemini 2.5. Gemini handles the heavy lifting of data processing and analysis, providing a strong technical foundation. Claude, on the other hand, refines and contextualizes the results, adding strategic depth and narrative clarity. This division of labor not only streamlines the workflow but also ensures that the final outputs are both accurate and meaningful. By combining these models, you can achieve a balance between technical precision and strategic insight. This approach is particularly valuable for professionals who need to manage complex projects, make data-driven decisions, or communicate findings effectively. Additional Insights Claude 4's autonomous memory system plays a crucial role in managing project contexts, making sure that no detail is overlooked, even in multi-stage workflows. This feature is especially useful for long-term projects that require consistent updates and contextual understanding. Meanwhile, Gemini's ability to process multimodal inputs and scale efficiently makes it indispensable for handling data-heavy tasks. Together, these models provide a comprehensive solution for professionals seeking to optimize their workflows with AI. Rather than viewing Claude 4 and Gemini 2.5 as standalone tools, consider them as collaborative partners. Their combined strengths allow you to approach tasks with both technical accuracy and strategic foresight. By integrating these models into your workflow, you can elevate your work to new levels of efficiency and impact. Whether you're analyzing data, crafting narratives, or making high-level decisions, this duo offers a powerful way to achieve your goals. Media Credit: Grace Leung Filed Under: AI, Guides Latest Geeky Gadgets Deals Disclosure: Some of our articles include affiliate links. If you buy something through one of these links, Geeky Gadgets may earn an affiliate commission. Learn about our Disclosure Policy.
